Stryker CEO: So far, so good after one year

Stryker CEO Kevin Lobo

Stryker's ($SYK) Kevin Lobo came aboard after the surprise ouster of Stephen MacMillan, and, in his first year at the helm of the Michigan device giant, the CEO has presided over a huge Chinese buyout, a lasting recall sting and expansions into new markets. Lobo sat down with The Kalamazoo Gazette to discuss all he's learned since his promotion and his plans to keep Stryker healthy and growing in the long term. Interview

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.